[
    [
        {
            "time": "",
            "original_text": "奥密克戎变异肆虐 国产新冠疫苗吃下定心丸：依然有效",
            "features": {
                "keywords": [
                    "奥密克戎",
                    "国产新冠疫苗",
                    "有效性"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "奥密克戎变异肆虐 国产新冠疫苗吃下定心丸：依然有效",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：重组新冠疫苗对奥密克戎变异株依然有效",
            "features": {
                "keywords": [
                    "智飞生物",
                    "重组新冠疫苗",
                    "奥密克戎",
                    "有效性"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：重组新冠疫苗对奥密克戎变异株依然有效",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司目前生产经营正常，所有业务均正常有序推进",
            "features": {
                "keywords": [
                    "智飞生物",
                    "生产经营",
                    "正常推进"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物：公司目前生产经营正常，所有业务均正常有序推进",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：与中科院微生物研究所合作研发的重组新冠疫苗（CHO细胞）达到WHO要求的有效性标准",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中科院",
                    "重组新冠疫苗",
                    "WHO",
                    "有效性标准"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：与中科院微生物研究所合作研发的重组新冠疫苗（CHO细胞）达到WHO要求的有效性标准",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 7,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司现有两款药品获批准上市，分别为重组结核杆菌融合蛋白与注射用母牛分枝杆菌",
            "features": {
                "keywords": [
                    "智飞生物",
                    "药品上市",
                    "重组结核杆菌融合蛋白",
                    "注射用母牛分枝杆菌"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：公司现有两款药品获批准上市，分别为重组结核杆菌融合蛋白与注射用母牛分枝杆菌",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：应付账款增加主要是按计划采购代理产品增加所致",
            "features": {
                "keywords": [
                    "智飞生物",
                    "应付账款",
                    "采购代理产品"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "智飞生物：应付账款增加主要是按计划采购代理产品增加所致",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "智飞生物：公司与中科院微生物研究所高度关注毒株变异情况并已开始相关研究",
            "features": {
                "keywords": [
                    "智飞生物",
                    "中科院",
                    "毒株变异",
                    "相关研究"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：公司与中科院微生物研究所高度关注毒株变异情况并已开始相关研究",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "茅指数与宁组合同台竞技，两大赛道谁技高一筹？",
            "features": {
                "keywords": [
                    "茅指数",
                    "宁组合",
                    "同台竞技",
                    "赛道对比"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合投资"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "茅指数与宁组合同台竞技，两大赛道谁技高一筹？",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]